Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Successful Air Business, Birchtech, to Lay Foundation for Commercial Water Treatment Expansion

In this episode of The Capital Compass, Ricki Lee sits down with Birchtech Corp. (TSX:BCHT; OTC:BCHT) , an environmental technology company best known for its long-running air purification business that removes mercury from power plant emissions. With the company n...
Ricki Lee | December 12, 2025 |

Bulls and Bears: Where Markets Stand Post-Election

The Market This Month – Episode 4 Title: Bulls and Bears: Where Markets Stand Post-Election Episode 4 Intro: The Canadian Securities Exchange presents your go-to source for trends in junior and small cap markets each month. Join host Anna Seren and financi...
Research | May 16, 2025 |

Buy recommendation for dynaCERT: GBC sees upside potential of over 300% to CAD 0.75!

Enter the green revolution: Cleantech stock with hydrogen potential! dynaCERT Inc. (ISIN: CA26780A1084 | TSX: DYA) is the focus of analyst Matthias Greiffenberger – and for good reason: The Canadian cleantech company is developing technologies to reduce emissions f...
Mario Hose | March 25, 2025 |

Can you get an investing edge using Emotional Intelligence?

Carolyn Stern , a certified Emotional Intelligence and Leadership Development Expert, and an award-winning author of The Emotionally Strong Leader joins The Market Online to discuss Emotional Intelligence in Investing and financial decision-making. Emotional intell...
Coreena Robertson | March 18, 2025 |

Decoding patient data sets to help clinical trials succeed

How well do you know your clinical patients? What if there was a way to uncover the hidden relationship between patients in clinical trials empowering scientists to make critical decisions. Lyndsay Malchuk from Stockhouse Publishing recently sat down with NetraMark Hold...
Lyndsay Malchuk | March 3, 2025 |

Revolutionizing immunotherapies with groundbreaking DPX platform

The following is a transcription of the above video, and The Market Online has edited it for clarity . BioVaxys Technology Corp (CSE:BIOV) is a Canadian-based clinical stage biopharmaceutical company focused on improving patient lives with novel immunotherapies. CE...
Lyndsay Malchuk | July 30, 2024 |

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...
Knox Henderson | July 2, 2024 |

Buzz on the Bullboards: Major developments amidst market dynamics

This week, the North American stock markets managed to showcase some contrasted performances. While the NASDAQ and S&P 500 reached record highs, driven by optimism around potential Federal Reserve rate cuts, the Dow Jones also enjoyed a solid rally. Meanwhile, the TS...
Jonathon Brown | May 16, 2024 |

Can NervGen keep a lid on explosive news?

Speculation of early “evidence” of successful proof-of-concept human trials sparks stock rallies Trial volunteers taking a placebo are offered the real deal in a follow-up trial as a “reward” The company&Clo...
Knox Henderson | March 20, 2024 |

Is this stunning 'evidence' that NervGen has the goods?

This could be the signal that tiny NervGen Pharma Corp. (TSX-V:NGEN; OTCQX:NGENF) is destined to be one of the top performing biotech startup stocks this year. It came in a seemingly innocuous podcast interview about the company’s ongoing Phase 1b/2...
Knox Henderson | February 1, 2024 |
1 2 3 4 5 6 7 8 9